[HTML][HTML] Previous disease-modifying treatments influence T lymphocyte kinetics in people with multiple sclerosis switching to ocrelizumab
G Abbadessa, G Miele, P Cavalla, P Valentino… - Journal of …, 2023 - Elsevier
Background Recently, concern has been raised about the influence of the previous disease-
modifying treatments (DMTs) on the clinical efficacy of ocrelizumab (OCR). We aimed to …
modifying treatments (DMTs) on the clinical efficacy of ocrelizumab (OCR). We aimed to …
[HTML][HTML] Blunted vaccines responses after ocrelizumab highlight need for immunizations prior to treatment
COVID-19 has reminded us that vaccines are lifesaving in high, middle and low-income
countries. People with multiple sclerosis (pwMS), who are prone to inflammation-triggered …
countries. People with multiple sclerosis (pwMS), who are prone to inflammation-triggered …
Ocrelizumab in relapsing and primary progressive multiple sclerosis: pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO
E Gibiansky, C Petry, F Mercier… - British journal of …, 2021 - Wiley Online Library
Aims Ocrelizumab is a humanized monoclonal antibody that selectively targets CD20‐
positive B cells and is indicated for treatment of patients with relapsing forms of multiple …
positive B cells and is indicated for treatment of patients with relapsing forms of multiple …
Rituximab-and ocrelizumab-induced early-and late-onset neutropenia in a multiple sclerosis patient
M Marrodan, J Laviano, S Oneto, FM Reino… - Neurological …, 2021 - Springer
Increasing evidence suggests B cells play a key role in multiple sclerosis (MS)
pathogenesis. Ocrelizumab (OCR), a humanized anti-CD20 IgG1 mAb, significantly …
pathogenesis. Ocrelizumab (OCR), a humanized anti-CD20 IgG1 mAb, significantly …
Ocrelizumab exposure in relapsing–remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension
Open-label extension (OLE) studies help inform long-term safety and efficacy of disease-
modifying therapies in multiple sclerosis (MS). We report exploratory analyses from a phase …
modifying therapies in multiple sclerosis (MS). We report exploratory analyses from a phase …
Lymphopenia in multiple sclerosis patients treated with ocrelizumab is associated with an effect on CD8 T cells
G Abbadessa, E Maida, G Miele, L Lavorgna… - Multiple Sclerosis and …, 2022 - Elsevier
Background In the phase III, OPERA I and OPERA II, clinical trial lymphopenia was reported
in 20.7% of relapsing–remitting multiple sclerosis (RRMS) patients taking Ocrelizumab …
in 20.7% of relapsing–remitting multiple sclerosis (RRMS) patients taking Ocrelizumab …
Rapidity of Onset of Ocrelizumab Clinical Efficacy in Relapsing Multiple Sclerosis (S31. 002)
Objective: To assess the dynamics of onset of ocrelizumab effect on the risk of relapse over
time and relapse rate by epoch compared with interferon beta-1a (IFNβ-1a) in the pooled …
time and relapse rate by epoch compared with interferon beta-1a (IFNβ-1a) in the pooled …
Efficacy of Rituximab Outlasts B-Cell Repopulation in Multiple Sclerosis: Time to Rethink Dosing?
R Claverie, M Perriguey, A Rico… - Neurology …, 2023 - AAN Enterprises
Background and Objectives Patients with multiple sclerosis (PwMS) receiving extended
dosing of rituximab (RTX) have exhibited no return of disease activity, which suggests that …
dosing of rituximab (RTX) have exhibited no return of disease activity, which suggests that …
[HTML][HTML] B cell depletion with ublituximab reshapes the T cell profile in multiple sclerosis patients
AE Lovett-Racke, M Gormley, Y Liu, Y Yang… - Journal of …, 2019 - Elsevier
Multiple sclerosis (MS) is a demyelinating disease of the central nervous system, thought to
be mediated by myelin-specific CD4+ T cells. However, B cell depletion has proven to be an …
be mediated by myelin-specific CD4+ T cells. However, B cell depletion has proven to be an …